New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Mike Murray, M.D., talks with KATU about the changes in winter sport-related injuries and offers helpful strategies to prevent breaks and fractures.

If you’ve been diagnosed with high blood pressure, there are lots of ways you can lower your blood pressure without prescription medications.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Learn how Medicaid support 79 million Americans.

A new type of surgical treatment for patients with benign prostatic hyperplasia (BPH) uses the power of water delivered with robotic precision to provide long-lasting BPH relief

Providence honors the donors who have given the gift of life, health and hope to those in need.

Breanne Brown, M.D., demonstrated simple exercises on KATU’s “Family Matters” to help viewers incorporate movement into their daily routines.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Our Thrivorship program offers access to Integrative Medicine therapies, including nutritional guidance, exercise and mindful movement—with a focus on emotional, mental and spiritual wellness.

A new treatment at Providence St. Joseph Hospital is offering hope for relief from osteoarthritis or other degenerative joint disorders

Providence Alaska Medical Center has earned a three‑year accreditation from the American College of Surgeons Commission on Cancer Accreditation Program.

Facilitated by the American Heart Association and Providence Saint Joseph Medical Center stroke team, stroke survivors and their loved ones are invited to join our support group.

Bariatric surgeon, Dr. Perryman, offers tips for weight loss.

For the second consecutive year, Providence Alaska Medical Center (PAMC) has been recognized by U.S. News & World Report for providing Alaskans with high-quality maternity care.

A major new study published in the prestigious journal Nature Medicine is offering renewed hope for cancer patients whose disease no longer responds to immunotherapy, and Providence St. Jude is proud

The ANCC Magnet Recognition Program® is the highest credential a healthcare organization can achieve.

Deborah Berini is joining Providence Alaska as chief executive on Feb. 23. Deb brings more than two decades of executive experience in health care systems across the country.

Dr. Natasha Edwin advocates for making more quality clinical trials available for patients in rural communities.

Learn how to protect your cervical health with regular screenings and prevention tips. Get expert advice from Providence on cervical cancer prevention.

Find support and share your journey by joining our monthly sessions designed to bring people together for connection, learning and encouragement.